#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-15	Transdiagnostic	_
1-2	16-26	multimodal	_
1-3	27-39	neuroimaging	_
1-4	40-42	in	_
1-5	43-52	psychosis	_
1-6	53-54	:	_
1-7	55-65	structural	_
1-8	66-67	,	_
1-9	68-81	resting-state	_
1-10	82-83	,	_
1-11	84-87	and	_
1-12	88-92	task	_
1-13	93-96	MRI	_
1-14	97-107	correlates	_
1-15	108-110	of	_
1-16	111-120	cognitive	_
1-17	121-128	control	_
1-18	129-139	Background	_
1-19	140-141	:	_
1-20	142-151	Disorders	_
1-21	152-156	with	_
1-22	157-166	psychotic	_
1-23	167-175	features	_
1-24	176-177	,	_
1-25	178-187	including	_
1-26	188-201	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-27	202-205	and	_
1-28	206-210	some	_
1-29	211-218	bipolar	_
1-30	219-227	disorder	_
1-31	228-229	,	_
1-32	230-233	are	_
1-33	234-244	associated	_
1-34	245-249	with	_
1-35	250-261	impairments	_
1-36	262-264	in	_
1-37	265-275	regulation	_
1-38	276-278	of	_
1-39	279-292	goal-directed	_
1-40	293-301	behavior	_
1-41	302-303	,	_
1-42	304-310	termed	_
1-43	311-320	cognitive	_
1-44	321-328	control	_
1-45	329-330	.	_

2-1	331-340	Cognitive	_
2-2	341-348	control	_
2-3	349-356	related	_
2-4	357-363	neural	_
2-5	364-375	alterations	_
2-6	376-380	have	_
2-7	381-385	been	_
2-8	386-393	studied	_
2-9	394-396	in	_
2-10	397-406	psychosis	_
2-11	407-408	.	_

3-1	409-416	However	_
3-2	417-418	,	_
3-3	419-426	studies	_
3-4	427-430	are	_
3-5	431-440	typically	_
3-6	441-449	unimodal	_
3-7	450-453	and	_
3-8	454-467	relationships	_
3-9	468-474	across	_
3-10	475-485	modalities	_
3-11	486-488	of	_
3-12	489-494	brain	_
3-13	495-503	function	_
3-14	504-507	and	_
3-15	508-517	structure	_
3-16	518-524	remain	_
3-17	525-532	unclear	_
3-18	533-534	.	_

4-1	535-539	Thus	_
4-2	540-541	,	_
4-3	542-544	we	_
4-4	545-554	performed	_
4-5	555-570	transdiagnostic	_
4-6	571-581	multimodal	_
4-7	582-590	analyses	_
4-8	591-593	to	_
4-9	594-601	examine	_
4-10	602-611	cognitive	_
4-11	612-619	control	_
4-12	620-627	related	_
4-13	628-634	neural	_
4-14	635-644	variation	_
4-15	645-647	in	_
4-16	648-657	psychosis	_
4-17	658-659	.	_

5-1	660-667	Methods	_
5-2	668-669	:	_
5-3	670-680	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
5-4	681-682	,	_
5-5	683-690	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
5-6	691-692	,	_
5-7	693-696	and	http://maven.renci.org/NeuroBridge/neurobridge#PhysicalMeasurement
5-8	697-704	working	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
5-9	705-711	memory	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
5-10	712-716	task	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
5-11	717-724	imaging	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask
5-12	725-728	for	_
5-13	729-731	31	_
5-14	732-740	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-15	741-742	,	_
5-16	743-745	27	_
5-17	746-753	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#BipolarDisorder
5-18	754-755	,	_
5-19	756-759	and	_
5-20	760-762	23	_
5-21	763-776	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-22	777-785	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-23	786-790	were	_
5-24	791-800	collected	_
5-25	801-804	and	_
5-26	805-814	processed	_
5-27	815-826	identically	_
5-28	827-829	to	_
5-29	830-833	the	_
5-30	834-839	Human	_
5-31	840-850	Connectome	_
5-32	851-858	Project	_
5-33	859-860	(	_
5-34	861-864	HCP	_
5-35	865-866	)	_
5-36	867-868	,	_
5-37	869-877	enabling	_
5-38	878-892	identification	_
5-39	893-895	of	_
5-40	896-909	relationships	_
5-41	910-914	with	_
5-42	915-920	prior	_
5-43	921-931	multimodal	_
5-44	932-936	work	_
5-45	937-938	.	_

6-1	939-942	Two	_
6-2	943-952	cognitive	_
6-3	953-960	control	_
6-4	961-968	related	_
6-5	969-980	independent	_
6-6	981-991	components	_
6-7	992-993	(	_
6-8	994-997	ICs	_
6-9	998-999	)	_
6-10	1000-1007	derived	_
6-11	1008-1012	from	_
6-12	1013-1016	the	_
6-13	1017-1020	HCP	_
6-14	1021-1026	using	_
6-15	1027-1035	multiset	_
6-16	1036-1045	canonical	_
6-17	1046-1057	correlation	_
6-18	1058-1066	analysis	_
6-19	1067-1068	+	_
6-20	1069-1074	joint	_
6-21	1075-1086	independent	_
6-22	1087-1096	component	_
6-23	1097-1105	analysis	_
6-24	1106-1107	(	_
6-25	1108-1117	mCCA+jICA	_
6-26	1118-1119	)	_
6-27	1120-1124	were	_
6-28	1125-1129	used	_
6-29	1130-1132	to	_
6-30	1133-1140	predict	_
6-31	1141-1152	performance	_
6-32	1153-1155	in	_
6-33	1156-1165	psychosis	_
6-34	1166-1167	.	_

7-1	1168-1170	De	_
7-2	1171-1175	novo	_
7-3	1176-1185	mCCA+jICA	_
7-4	1186-1189	was	_
7-5	1190-1199	performed	_
7-6	1200-1203	and	_
7-7	1204-1211	results	_
7-8	1212-1222	correlated	_
7-9	1223-1227	with	_
7-10	1228-1237	cognitive	_
7-11	1238-1245	control	_
7-12	1246-1247	.	_

8-1	1248-1255	Results	_
8-2	1256-1257	:	_
8-3	1258-1259	A	_
8-4	1260-1266	priori	_
8-5	1267-1274	working	_
8-6	1275-1281	memory	_
8-7	1282-1285	and	_
8-8	1286-1294	cortical	_
8-9	1295-1304	thickness	_
8-10	1305-1309	maps	_
8-11	1310-1323	significantly	_
8-12	1324-1333	predicted	_
8-13	1334-1343	cognitive	_
8-14	1344-1351	control	_
8-15	1352-1354	in	_
8-16	1355-1364	psychosis	_
8-17	1365-1366	.	_

9-1	1367-1369	De	_
9-2	1370-1374	novo	_
9-3	1375-1384	mCCA+jICA	_
9-4	1385-1395	identified	_
9-5	1396-1398	an	_
9-6	1399-1401	IC	_
9-7	1402-1412	correlated	_
9-8	1413-1417	with	_
9-9	1418-1427	cognitive	_
9-10	1428-1435	control	_
9-11	1436-1440	that	_
9-12	1441-1445	also	_
9-13	1446-1459	discriminated	_
9-14	1460-1466	groups	_
9-15	1467-1468	.	_

10-1	1469-1479	Structural	_
10-2	1480-1493	contributions	_
10-3	1494-1502	included	_
10-4	1503-1510	insular	_
10-5	1511-1514	and	_
10-6	1515-1524	cingulate	_
10-7	1525-1532	regions	_
10-8	1533-1534	;	_
10-9	1535-1539	task	_
10-10	1540-1553	contributions	_
10-11	1554-1562	included	_
10-12	1563-1573	precentral	_
10-13	1574-1575	,	_
10-14	1576-1585	posterior	_
10-15	1586-1594	parietal	_
10-16	1595-1596	,	_
10-17	1597-1606	cingulate	_
10-18	1607-1608	,	_
10-19	1609-1612	and	_
10-20	1613-1619	visual	_
10-21	1620-1627	regions	_
10-22	1628-1629	;	_
10-23	1630-1633	and	_
10-24	1634-1647	resting-state	_
10-25	1648-1661	contributions	_
10-26	1662-1673	highlighted	_
10-27	1674-1683	canonical	_
10-28	1684-1691	network	_
10-29	1692-1704	organization	_
10-30	1705-1706	.	_

11-1	1707-1716	Follow-up	_
11-2	1717-1725	analyses	_
11-3	1726-1735	suggested	_
11-4	1736-1748	correlations	_
11-5	1749-1753	with	_
11-6	1754-1763	cognitive	_
11-7	1764-1771	control	_
11-8	1772-1776	were	_
11-9	1777-1786	primarily	_
11-10	1787-1797	influenced	_
11-11	1798-1800	by	_
11-12	1801-1814	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-13	1815-1823	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-14	1824-1825	.	_

12-1	1826-1837	Conclusions	_
12-2	1838-1839	:	_
12-3	1840-1841	A	_
12-4	1842-1848	priori	_
12-5	1849-1852	and	_
12-6	1853-1855	de	_
12-7	1856-1860	novo	_
12-8	1861-1868	imaging	_
12-9	1869-1879	replicably	_
12-10	1880-1890	identified	_
12-11	1891-1892	a	_
12-12	1893-1896	set	_
12-13	1897-1899	of	_
12-14	1900-1912	interrelated	_
12-15	1913-1921	patterns	_
12-16	1922-1928	across	_
12-17	1929-1939	modalities	_
12-18	1940-1943	and	_
12-19	1944-1947	the	_
12-20	1948-1968	healthy-to-psychosis	_
12-21	1969-1977	spectrum	_
12-22	1978-1988	suggesting	_
12-23	1989-1999	robustness	_
12-24	2000-2002	of	_
12-25	2003-2008	these	_
12-26	2009-2017	features	_
12-27	2018-2019	.	_

13-1	2020-2033	Relationships	_
13-2	2034-2041	between	_
13-3	2042-2049	imaging	_
13-4	2050-2053	and	_
13-5	2054-2063	cognitive	_
13-6	2064-2071	control	_
13-7	2072-2083	performance	_
13-8	2084-2091	suggest	_
13-9	2092-2098	shared	_
13-10	2099-2113	symptomatology	_
13-11	2114-2117	may	_
13-12	2118-2120	be	_
13-13	2121-2124	key	_
13-14	2125-2127	to	_
13-15	2128-2139	identifying	_
13-16	2140-2155	transdiagnostic	_
13-17	2156-2169	relationships	_
13-18	2170-2172	in	_
13-19	2173-2182	psychosis	_
13-20	2183-2184	.	_

14-1	2185-2192	Methods	_
14-2	2193-2194	:	_
14-3	2195-2207	Participants	_
14-4	2208-2209	:	_
14-5	2210-2222	Participants	_
14-6	2223-2227	were	_
14-7	2228-2237	recruited	_
14-8	2238-2242	from	_
14-9	2243-2244	a	_
14-10	2245-2252	broader	_
14-11	2253-2258	study	_
14-12	2259-2261	of	_
14-13	2262-2268	neural	_
14-14	2269-2280	alterations	_
14-15	2281-2283	in	_
14-16	2284-2293	psychosis	_
14-17	2294-2297	and	_
14-18	2298-2306	included	_
14-19	2307-2314	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
14-20	2315-2323	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
14-21	2324-2325	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
14-22	2326-2328	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
14-23	2329-2330	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
14-24	2331-2332	,	_
14-25	2333-2346	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
14-26	2347-2349	or	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
14-27	2350-2365	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
14-28	2366-2374	disorder	http://maven.renci.org/NeuroBridge/neurobridge#SchizoaffectiveDisorder
14-29	2375-2376	(	_
14-30	2377-2379	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
14-31	2380-2381	)	_
14-32	2382-2383	,	_
14-33	2384-2387	and	_
14-34	2388-2395	bipolar	_
14-35	2396-2404	disorder	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
14-36	2405-2406	(	http://maven.renci.org/NeuroBridge/neurobridge#MoodDisorder
14-37	2407-2409	BP	_
14-38	2410-2411	)	_
14-39	2412-2413	.	_

15-1	2414-2419	Prior	_
15-2	2420-2422	to	_
15-3	2423-2428	image	_
15-4	2429-2443	pre-processing	_
15-5	2444-2445	,	_
15-6	2446-2451	there	_
15-7	2452-2456	were	_
15-8	2457-2461	n=35	_
15-9	2462-2464	HC	_
15-10	2465-2466	,	_
15-11	2467-2471	n=36	_
15-12	2472-2474	BP	_
15-13	2475-2476	,	_
15-14	2477-2480	and	_
15-15	2481-2485	n=31	_
15-16	2486-2488	SZ	_
15-17	2489-2498	available	_
15-18	2499-2500	.	_

16-1	2501-2503	Of	_
16-2	2504-2508	this	_
16-3	2509-2510	,	_
16-4	2511-2518	n=31/30	_
16-5	2519-2520	*	_
16-6	2521-2523	HC	_
16-7	2524-2525	,	_
16-8	2526-2530	n=27	_
16-9	2531-2533	BP	_
16-10	2534-2535	,	_
16-11	2536-2539	and	_
16-12	2540-2544	n=23	_
16-13	2545-2547	SZ	_
16-14	2548-2551	had	_
16-15	2552-2555	the	_
16-16	2556-2565	requisite	_
16-17	2566-2570	data	_
16-18	2571-2574	for	_
16-19	2575-2584	inclusion	_
16-20	2585-2587	in	_
16-21	2588-2592	this	_
16-22	2593-2598	study	_
16-23	2599-2600	(	_
16-24	2601-2602	*	_
16-25	2603-2606	see	_
16-26	2607-2617	supplement	_
16-27	2618-2619	)	_
16-28	2620-2621	.	_

17-1	2622-2634	Participants	_
17-2	2635-2639	were	_
17-3	2640-2649	recruited	_
17-4	2650-2654	from	_
17-5	2655-2663	clinical	_
17-6	2664-2667	and	_
17-7	2668-2677	community	_
17-8	2678-2686	settings	_
17-9	2687-2689	in	_
17-10	2690-2695	Saint	_
17-11	2696-2701	Louis	_
17-12	2702-2703	.	_

18-1	2704-2716	Participants	_
18-2	2717-2720	had	_
18-3	2721-2723	no	_
18-4	2724-2733	substance	_
18-5	2734-2737	use	_
18-6	2738-2746	disorder	_
18-7	2747-2749	in	_
18-8	2750-2753	the	_
18-9	2754-2759	prior	_
18-10	2760-2763	six	_
18-11	2764-2770	months	_
18-12	2771-2772	,	_
18-13	2773-2775	no	_
18-14	2776-2786	clinically	_
18-15	2787-2798	significant	_
18-16	2799-2803	head	_
18-17	2804-2810	trauma	_
18-18	2811-2812	,	_
18-19	2813-2816	and	_
18-20	2817-2819	no	_
18-21	2820-2832	neurological	_
18-22	2833-2841	diseases	_
18-23	2842-2843	.	_

19-1	2844-2851	Patient	_
19-2	2852-2865	participation	_
19-3	2866-2874	criteria	_
19-4	2875-2883	included	_
19-5	2884-2885	:	_
19-6	2886-2892	DSM-IV	_
19-7	2893-2902	diagnosis	_
19-8	2903-2905	of	_
19-9	2906-2908	BP	http://maven.renci.org/NeuroBridge/neurobridge#Thing
19-10	2909-2911	or	_
19-11	2912-2914	SZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
19-12	2915-2916	,	_
19-13	2917-2920	age	_
19-14	2921-2926	18–30	_
19-15	2927-2928	,	_
19-16	2929-2932	and	_
19-17	2933-2939	stable	_
19-18	2940-2950	outpatient	_
19-19	2951-2953	or	_
19-20	2954-2961	partial	_
19-21	2962-2970	hospital	_
19-22	2971-2977	status	_
19-23	2978-2979	.	_

20-1	2980-2982	HC	_
20-2	2983-2987	were	_
20-3	2988-2997	recruited	_
20-4	2998-3000	to	_
20-5	3001-3005	have	_
20-6	3006-3013	similar	_
20-7	3014-3026	demographics	_
20-8	3027-3028	(	_
20-9	3029-3032	age	_
20-10	3033-3034	,	_
20-11	3035-3041	gender	_
20-12	3042-3043	,	_
20-13	3044-3052	parental	_
20-14	3053-3058	level	_
20-15	3059-3061	of	_
20-16	3062-3071	education	_
20-17	3072-3073	)	_
20-18	3074-3076	as	_
20-19	3077-3085	patients	_
20-20	3086-3087	.	_

21-1	3088-3090	HC	_
21-2	3091-3104	participation	_
21-3	3105-3113	criteria	_
21-4	3114-3122	included	_
21-5	3123-3124	:	_
21-6	3125-3127	no	_
21-7	3128-3135	history	_
21-8	3136-3138	of	_
21-9	3139-3145	DSM-IV	_
21-10	3146-3155	psychotic	_
21-11	3156-3164	disorder	_
21-12	3165-3168	and	_
21-13	3169-3171	no	_
21-14	3172-3181	cognitive	_
21-15	3182-3191	enhancing	_
21-16	3192-3194	or	_
21-17	3195-3207	psychotropic	_
21-18	3208-3218	medication	_
21-19	3219-3222	for	_
21-20	3223-3228	prior	_
21-21	3229-3234	three	_
21-22	3235-3241	months	_
21-23	3242-3243	.	_

22-1	3244-3249	Study	_
22-2	3250-3260	procedures	_
22-3	3261-3265	were	_
22-4	3266-3274	approved	_
22-5	3275-3277	by	_
22-6	3278-3281	the	_
22-7	3282-3292	Washington	_
22-8	3293-3303	University	_
22-9	3304-3317	Institutional	_
22-10	3318-3324	Review	_
22-11	3325-3330	Board	_
22-12	3331-3334	and	_
22-13	3335-3338	all	_
22-14	3339-3351	participants	_
22-15	3352-3356	gave	_
22-16	3357-3364	written	_
22-17	3365-3373	informed	_
22-18	3374-3381	consent	_
22-19	3382-3383	.	_

23-1	3384-3394	Behavioral	_
23-2	3395-3405	assessment	_
23-3	3406-3407	:	_
23-4	3408-3409	A	_
23-5	3410-3419	composite	_
23-6	3420-3427	measure	_
23-7	3428-3430	of	_
23-8	3431-3440	cognitive	_
23-9	3441-3448	control	_
23-10	3449-3452	was	_
23-11	3453-3462	generated	_
23-12	3463-3466	for	_
23-13	3467-3471	each	_
23-14	3472-3483	participant	_
23-15	3484-3488	from	_
23-16	3489-3494	their	_
23-17	3495-3506	performance	_
23-18	3507-3509	on	_
23-19	3510-3514	four	_
23-20	3515-3520	tasks	_
23-21	3521-3522	(	_
23-22	3523-3526	see	_
23-23	3527-3537	supplement	_
23-24	3538-3541	for	_
23-25	3542-3549	details	_
23-26	3550-3552	on	_
23-27	3553-3557	each	_
23-28	3558-3562	task	_
23-29	3563-3564	)	_
23-30	3565-3566	:	_
23-31	3567-3577	In-scanner	_
23-32	3578-3584	N-Back	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
23-33	3585-3589	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
23-34	3590-3591	;	_
23-35	3592-3593	2	_
23-36	3594-3595	)	_
23-37	3596-3599	Out	_
23-38	3600-3602	of	_
23-39	3603-3610	scanner	_
23-40	3611-3617	letter	_
23-41	3618-3624	N-Back	_
23-42	3625-3629	task	_
23-43	3630-3634	from	_
23-44	3635-3638	the	_
23-45	3639-3643	Penn	_
23-46	3644-3656	Computerized	_
23-47	3657-3675	Neuropsychological	_
23-48	3676-3683	battery	_
23-49	3684-3685	(	_
23-50	3686-3693	PennCNP	_
23-51	3694-3695	)	_
23-52	3696-3697	;	_
23-53	3698-3699	3	_
23-54	3700-3701	)	_
23-55	3702-3713	Progressive	_
23-56	3714-3722	matrices	_
23-57	3723-3727	from	_
23-58	3728-3731	the	_
23-59	3732-3739	PennCNP	_
23-60	3740-3741	;	_
23-61	3742-3745	and	_
23-62	3746-3747	,	_
23-63	3748-3749	4	_
23-64	3750-3751	)	_
23-65	3752-3756	Penn	_
23-66	3757-3768	Conditional	_
23-67	3769-3778	Exclusion	_
23-68	3779-3783	Task	_
23-69	3784-3792	accuracy	_
23-70	3793-3794	.	_

24-1	3795-3806	Performance	_
24-2	3807-3809	on	_
24-3	3810-3814	each	_
24-4	3815-3819	task	_
24-5	3820-3823	was	_
24-6	3824-3836	individually	_
24-7	3837-3845	Z-scored	_
24-8	3846-3849	and	_
24-9	3850-3858	averaged	_
24-10	3859-3861	to	_
24-11	3862-3870	generate	_
24-12	3871-3874	the	_
24-13	3875-3884	composite	_
24-14	3885-3892	measure	_
24-15	3893-3894	.	_

25-1	3895-3899	This	_
25-2	3900-3909	composite	_
25-3	3910-3913	had	_
25-4	3914-3915	a	_
25-5	3916-3924	Cronbach	_
25-6	3925-3926	’	_
25-7	3927-3928	s	_
25-8	3929-3934	alpha	_
25-9	3935-3937	of	_
25-10	3938-3942	0.75	_
25-11	3943-3944	,	_
25-12	3945-3955	suggesting	_
25-13	3956-3960	good	_
25-14	3961-3969	internal	_
25-15	3970-3981	consistency	_
25-16	3982-3983	.	_

26-1	3984-3996	Neuroimaging	_
26-2	3997-4007	collection	_
26-3	4008-4011	and	_
26-4	4012-4026	pre-processing	_
26-5	4027-4039	Participants	_
26-6	4040-4044	were	_
26-7	4045-4052	scanned	_
26-8	4053-4055	at	_
26-9	4056-4066	Washington	_
26-10	4067-4077	University	_
26-11	4078-4080	in	_
26-12	4081-4084	St.	_
26-13	4085-4090	Louis	_
26-14	4091-4096	using	_
26-15	4097-4098	a	_
26-16	4099-4109	customized	_
26-17	4110-4117	Siemens	_
26-18	4118-4119	“	_
26-19	4120-4130	Connectome	_
26-20	4131-4132	”	_
26-21	4133-4140	scanner	_
26-22	4141-4150	developed	_
26-23	4151-4154	for	_
26-24	4155-4158	the	_
26-25	4159-4162	HCP	_
26-26	4163-4164	.	_

27-1	4165-4167	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
27-2	4168-4171	and	_
27-3	4172-4174	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging
27-4	4175-4179	were	_
27-5	4180-4188	acquired	_
27-6	4189-4191	at	_
27-7	4192-4197	0.7mm	_
27-8	4198-4207	isotropic	_
27-9	4208-4218	resolution	_
27-10	4219-4222	and	_
27-11	4223-4227	BOLD	_
27-12	4228-4235	imaging	_
27-13	4236-4240	were	_
27-14	4241-4250	collected	_
27-15	4251-4253	at	_
27-16	4254-4257	2mm	_
27-17	4258-4267	isotropic	_
27-18	4268-4278	resolution	_
27-19	4279-4283	with	_
27-20	4284-4289	720ms	_
27-21	4290-4292	TR	_
27-22	4293-4294	.	_

28-1	4295-4299	Data	_
28-2	4300-4304	were	_
28-3	4305-4318	pre-processed	_
28-4	4319-4324	using	_
28-5	4325-4328	the	_
28-6	4329-4332	HCP	_
28-7	4333-4342	pipelines	_
28-8	4343-4346	and	_
28-9	4347-4354	further	_
28-10	4355-4364	processed	_
28-11	4365-4367	to	_
28-12	4368-4376	generate	_
28-13	4377-4380	the	_
28-14	4381-4386	final	_
28-15	4387-4394	imaging	_
28-16	4395-4403	measures	_
28-17	4404-4408	used	_
28-18	4409-4411	in	_
28-19	4412-4415	the	_
28-20	4416-4423	present	_
28-21	4424-4429	study	_
28-22	4430-4432	as	_
28-23	4433-4436	was	_
28-24	4437-4441	done	_
28-25	4442-4444	in	_
28-26	4445-4446	.	_

29-1	4447-4452	Three	_
29-2	4453-4460	imaging	_
29-3	4461-4471	modalities	_
29-4	4472-4476	were	_
29-5	4477-4481	used	_
29-6	4482-4483	:	_
29-7	4484-4485	1	_
29-8	4486-4487	)	_
29-9	4488-4496	cortical	_
29-10	4497-4506	thickness	_
29-11	4507-4508	(	_
29-12	4509-4513	sMRI	_
29-13	4514-4515	)	_
29-14	4516-4517	;	_
29-15	4518-4519	2	_
29-16	4520-4521	)	_
29-17	4522-4529	resting	_
29-18	4530-4535	state	_
29-19	4536-4546	functional	_
29-20	4547-4559	connectivity	_
29-21	4560-4571	correlation	_
29-22	4572-4580	matrices	_
29-23	4581-4582	(	_
29-24	4583-4590	rsfcMRI	_
29-25	4591-4592	)	_
29-26	4593-4602	generated	_
29-27	4603-4608	using	_
29-28	4609-4617	cortical	_
29-29	4618-4619	,	_
29-30	4620-4630	cerebellar	_
29-31	4631-4632	,	_
29-32	4633-4636	and	_
29-33	4637-4648	subcortical	_
29-34	4649-4656	parcels	_
29-35	4657-4661	from	_
29-36	4662-4672	Freesurfer	_
29-37	4673-4674	;	_
29-38	4675-4678	and	_
29-39	4679-4680	,	_
29-40	4681-4682	3	_
29-41	4683-4684	)	_
29-42	4685-4688	the	_
29-43	4689-4692	HCP	http://maven.renci.org/NeuroBridge/neurobridge#Thing
29-44	4693-4699	N-back	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
29-45	4700-4707	working	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
29-46	4708-4714	memory	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
29-47	4715-4719	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
29-48	4720-4724	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
29-49	4725-4726	(	_
29-50	4727-4732	tfMRI	_
29-51	4733-4734	)	_
29-52	4735-4736	–	_
29-53	4737-4747	activation	_
29-54	4748-4750	in	_
29-55	4751-4754	the	_
29-56	4755-4761	2-back	_
29-57	4762-4771	condition	_
29-58	4772-4773	(	_
29-59	4774-4777	see	_
29-60	4778-4788	supplement	_
29-61	4789-4790	)	_
29-62	4791-4792	.	_

30-1	4793-4805	Relationship	_
30-2	4806-4808	to	_
30-3	4809-4810	a	_
30-4	4811-4817	priori	_
30-5	4818-4827	normative	_
30-6	4828-4838	multimodal	_
30-7	4839-4849	correlates	_
30-8	4850-4852	of	_
30-9	4853-4862	cognitive	_
30-10	4863-4870	control	_
30-11	4871-4872	:	_
30-12	4873-4876	Our	_
30-13	4877-4885	previous	_
30-14	4886-4890	work	_
30-15	4891-4896	using	_
30-16	4897-4906	mCCA+jICA	_
30-17	4907-4917	identified	_
30-18	4918-4928	replicable	_
30-19	4929-4939	multimodal	_
30-20	4940-4948	patterns	_
30-21	4949-4953	from	_
30-22	4954-4957	two	_
30-23	4958-4967	mCCA+jICA	_
30-24	4968-4978	components	_
30-25	4979-4983	that	_
30-26	4984-4988	were	_
30-27	4989-5002	significantly	_
30-28	5003-5010	related	_
30-29	5011-5013	to	_
30-30	5014-5023	cognitive	_
30-31	5024-5031	control	_
30-32	5032-5034	in	_
30-33	5035-5042	healthy	_
30-34	5043-5055	participants	_
30-35	5056-5058	in	_
30-36	5059-5062	the	_
30-37	5063-5066	HCP	http://maven.renci.org/NeuroBridge/neurobridge#Thing
30-38	5067-5068	.	_

31-1	5069-5071	We	_
31-2	5072-5081	performed	_
31-3	5082-5084	an	_
31-4	5085-5093	analysis	_
31-5	5094-5096	to	_
31-6	5097-5106	determine	_
31-7	5107-5114	whether	_
31-8	5115-5123	patterns	_
31-9	5124-5128	from	_
31-10	5129-5134	these	_
31-11	5135-5138	two	_
31-12	5139-5149	components	_
31-13	5150-5154	also	_
31-14	5155-5164	predicted	_
31-15	5165-5174	cognitive	_
31-16	5175-5182	control	_
31-17	5183-5185	in	_
31-18	5186-5189	the	_
31-19	5190-5197	present	_
31-20	5198-5210	participants	_
31-21	5211-5212	.	_

32-1	5213-5218	Given	_
32-2	5219-5223	that	_
32-3	5224-5228	data	_
32-4	5229-5233	were	_
32-5	5234-5243	collected	_
32-6	5244-5247	and	_
32-7	5248-5257	processed	_
32-8	5258-5269	identically	_
32-9	5270-5271	,	_
32-10	5272-5274	we	_
32-11	5275-5283	directly	_
32-12	5284-5291	applied	_
32-13	5292-5295	the	_
32-14	5296-5301	three	_
32-15	5302-5310	relevant	_
32-16	5311-5321	modalities	_
32-17	5322-5326	from	_
32-18	5327-5332	these	_
32-19	5333-5336	two	_
32-20	5337-5347	components	_
32-21	5348-5352	from	_
32-22	5353-5356	the	_
32-23	5357-5362	prior	_
32-24	5363-5368	study	_
32-25	5369-5371	to	_
32-26	5372-5375	the	_
32-27	5376-5382	source	_
32-28	5383-5387	data	_
32-29	5388-5392	from	_
32-30	5393-5396	the	_
32-31	5397-5404	present	_
32-32	5405-5411	cohort	_
32-33	5412-5413	(	_
32-34	5414-5422	referred	_
32-35	5423-5425	to	_
32-36	5426-5428	as	_
32-37	5429-5440	HCP_gC1_IC3	_
32-38	5441-5444	and	_
32-39	5445-5456	HCP_gC1_IC7	_
32-40	5457-5458	,	_
32-41	5459-5462	see	_
32-42	5463-5473	supplement	_
32-43	5474-5475	)	_
32-44	5476-5477	.	_

33-1	5478-5482	This	_
33-2	5483-5492	generated	_
33-3	5493-5494	a	_
33-4	5495-5498	set	_
33-5	5499-5501	of	_
33-6	5502-5518	subject-specific	_
33-7	5519-5526	weights	_
33-8	5527-5530	for	_
33-9	5531-5534	the	_
33-10	5535-5542	present	_
33-11	5543-5549	cohort	_
33-12	5550-5563	corresponding	_
33-13	5564-5566	to	_
33-14	5567-5570	the	_
33-15	5571-5577	extent	_
33-16	5578-5580	to	_
33-17	5581-5586	which	_
33-18	5587-5588	a	_
33-19	5589-5595	priori	_
33-20	5596-5606	components	_
33-21	5607-5616	reflected	_
33-22	5617-5620	the	_
33-23	5621-5628	present	_
33-24	5629-5633	data	_
33-25	5634-5635	(	_
33-26	5636-5639	see	_
33-27	5640-5650	supplement	_
33-28	5651-5652	)	_
33-29	5653-5654	.	_

34-1	5655-5664	Resultant	_
34-2	5665-5672	weights	_
34-3	5673-5677	were	_
34-4	5678-5688	correlated	_
34-5	5689-5693	with	_
34-6	5694-5697	the	_
34-7	5698-5707	composite	_
34-8	5708-5717	cognitive	_
34-9	5718-5725	control	_
34-10	5726-5733	measure	_
34-11	5734-5735	.	_

35-1	5736-5745	mCCA+jICA	_
35-2	5746-5756	multimodal	_
35-3	5757-5764	imaging	_
35-4	5765-5773	analysis	_
35-5	5774-5775	:	_
35-6	5776-5778	We	_
35-7	5779-5783	also	_
35-8	5784-5794	identified	_
35-9	5795-5804	mCCA+jICA	_
35-10	5805-5815	components	_
35-11	5816-5818	de	_
35-12	5819-5823	novo	_
35-13	5824-5826	in	_
35-14	5827-5830	the	_
35-15	5831-5840	psychosis	_
35-16	5841-5845	data	_
35-17	5846-5849	set	_
35-18	5850-5851	.	_

36-1	5852-5860	Multiset	_
36-2	5861-5870	canonical	_
36-3	5871-5882	correlation	_
36-4	5883-5891	analysis	_
36-5	5892-5896	with	_
36-6	5897-5902	joint	_
36-7	5903-5914	independent	_
36-8	5915-5924	component	_
36-9	5925-5933	analysis	_
36-10	5934-5935	(	_
36-11	5936-5945	mCCA+jICA	_
36-12	5946-5947	)	_
36-13	5948-5950	is	_
36-14	5951-5953	an	_
36-15	5954-5966	unsupervised	_
36-16	5967-5975	analysis	_
36-17	5976-5985	framework	_
36-18	5986-5990	that	_
36-19	5991-6001	identifies	_
36-20	6002-6015	relationships	_
36-21	6016-6022	across	_
36-22	6023-6033	modalities	_
36-23	6034-6037	and	_
36-24	6038-6048	decomposes	_
36-25	6049-6053	data	_
36-26	6054-6056	to	_
36-27	6057-6063	reveal	_
36-28	6064-6073	maximally	_
36-29	6074-6085	independent	_
36-30	6086-6092	latent	_
36-31	6093-6100	sources	_
36-32	6101-6103	of	_
36-33	6104-6112	variance	_
36-34	6113-6114	(	_
36-35	6115-6118	see	_
36-36	6119-6129	supplement	_
36-37	6130-6131	)	_
36-38	6132-6133	.	_

37-1	6134-6141	Briefly	_
37-2	6142-6143	,	_
37-3	6144-6148	mCCA	_
37-4	6149-6154	first	_
37-5	6155-6162	aligned	_
37-6	6163-6166	the	_
37-7	6167-6172	three	_
37-8	6173-6180	imaging	_
37-9	6181-6191	modalities	_
37-10	6192-6194	in	_
37-11	6195-6200	order	_
37-12	6201-6203	to	_
37-13	6204-6212	simplify	_
37-14	6213-6216	the	_
37-15	6217-6230	correlational	_
37-16	6231-6240	structure	_
37-17	6241-6244	and	_
37-18	6245-6253	maximize	_
37-19	6254-6267	inter-subject	_
37-20	6268-6279	covariation	_
37-21	6280-6281	.	_

38-1	6282-6286	Next	_
38-2	6287-6288	,	_
38-3	6289-6293	jICA	_
38-4	6294-6303	maximized	_
38-5	6304-6311	spatial	_
38-6	6312-6324	independence	_
38-7	6325-6333	yielding	_
38-8	6334-6335	a	_
38-9	6336-6339	set	_
38-10	6340-6342	of	_
38-11	6343-6344	9	_
38-12	6345-6356	independent	_
38-13	6357-6367	components	_
38-14	6368-6369	(	_
38-15	6370-6373	ICs	_
38-16	6374-6375	)	_
38-17	6376-6377	.	_

39-1	6378-6382	Each	_
39-2	6383-6385	IC	_
39-3	6386-6395	contained	_
39-4	6396-6397	a	_
39-5	6398-6401	set	_
39-6	6402-6404	of	_
39-7	6405-6411	linked	_
39-8	6412-6422	modalities	_
39-9	6423-6432	including	_
39-10	6433-6437	maps	_
39-11	6438-6440	of	_
39-12	6441-6449	cortical	_
39-13	6450-6459	thickness	_
39-14	6460-6461	(	_
39-15	6462-6466	sMRI	_
39-16	6467-6468	)	_
39-17	6469-6472	and	_
39-18	6473-6480	working	_
39-19	6481-6487	memory	_
39-20	6488-6492	task	_
39-21	6493-6503	activation	_
39-22	6504-6505	(	_
39-23	6506-6511	tfMRI	_
39-24	6512-6513	)	_
39-25	6514-6515	,	_
39-26	6516-6519	and	_
39-27	6520-6521	a	_
39-28	6522-6533	parcel-wise	_
39-29	6534-6545	correlation	_
39-30	6546-6552	matrix	_
39-31	6553-6554	(	_
39-32	6555-6562	rsfcMRI	_
39-33	6563-6564	)	_
39-34	6565-6566	.	_

40-1	6567-6571	Each	_
40-2	6572-6574	IC	_
40-3	6575-6578	had	_
40-4	6579-6580	a	_
40-5	6581-6594	corresponding	_
40-6	6595-6598	set	_
40-7	6599-6601	of	_
40-8	6602-6618	subject-specific	_
40-9	6619-6626	weights	_
40-10	6627-6631	that	_
40-11	6632-6641	reflected	_
40-12	6642-6645	the	_
40-13	6646-6652	extent	_
40-14	6653-6655	to	_
40-15	6656-6661	which	_
40-16	6662-6663	a	_
40-17	6664-6669	given	_
40-18	6670-6672	IC	_
40-19	6673-6682	comprised	_
40-20	6683-6686	the	_
40-21	6687-6698	participant	_
40-22	6699-6700	’	_
40-23	6701-6702	s	_
40-24	6703-6711	original	_
40-25	6712-6716	data	_
40-26	6717-6718	.	_

41-1	6719-6724	These	_
41-2	6725-6732	weights	_
41-3	6733-6737	were	_
41-4	6738-6742	then	_
41-5	6743-6747	used	_
41-6	6748-6751	for	_
41-7	6752-6763	statistical	_
41-8	6764-6772	analyses	_
41-9	6773-6775	to	_
41-10	6776-6784	identify	_
41-11	6785-6799	brain-behavior	_
41-12	6800-6813	relationships	_
41-13	6814-6817	and	_
41-14	6818-6824	assess	_
41-15	6825-6830	group	_
41-16	6831-6847	discriminability	_
41-17	6848-6849	(	_
41-18	6850-6853	see	_
41-19	6854-6864	supplement	_
41-20	6865-6866	)	_
41-21	6867-6868	.	_

42-1	6869-6880	Statistical	_
42-2	6881-6889	analyses	_
42-3	6890-6891	:	_
42-4	6892-6903	Statistical	_
42-5	6904-6912	analyses	_
42-6	6913-6917	were	_
42-7	6918-6927	performed	_
42-8	6928-6930	in	_
42-9	6931-6935	SPSS	_
42-10	6936-6939	and	_
42-11	6940-6946	MATLAB	_
42-12	6947-6951	with	_
42-13	6952-6960	multiple	_
42-14	6961-6971	comparison	_
42-15	6972-6982	correction	_
42-16	6983-6988	using	_
42-17	6989-6992	FDR	_
42-18	6993-6994	.	_

43-1	6995-6998	For	_
43-2	6999-7011	correlations	_
43-3	7012-7019	between	_
43-4	7020-7036	subject-specific	_
43-5	7037-7044	weights	_
43-6	7045-7048	and	_
43-7	7049-7058	cognitive	_
43-8	7059-7066	control	_
43-9	7067-7078	performance	_
43-10	7079-7080	,	_
43-11	7081-7088	partial	_
43-12	7089-7100	correlation	_
43-13	7101-7104	was	_
43-14	7105-7109	used	_
43-15	7110-7112	to	_
43-16	7113-7120	correct	_
43-17	7121-7124	for	_
43-18	7125-7136	differences	_
43-19	7137-7139	in	_
43-20	7140-7145	group	_
43-21	7146-7151	means	_
43-22	7152-7153	.	_

44-1	7154-7156	We	_
44-2	7157-7165	assessed	_
44-3	7166-7171	group	_
44-4	7172-7186	discrimination	_
44-5	7187-7198	performance	_
44-6	7199-7201	of	_
44-7	7202-7206	each	_
44-8	7207-7209	IC	_
44-9	7210-7215	using	_
44-10	7216-7228	multivariate	_
44-11	7229-7237	analysis	_
44-12	7238-7240	of	_
44-13	7241-7249	variance	_
44-14	7250-7251	(	_
44-15	7252-7258	MANOVA	_
44-16	7259-7260	)	_
44-17	7261-7263	in	_
44-18	7264-7269	which	_
44-19	7270-7275	group	_
44-20	7276-7279	was	_
44-21	7280-7284	used	_
44-22	7285-7287	to	_
44-23	7288-7295	predict	_
44-24	7296-7299	all	_
44-25	7300-7305	three	_
44-26	7306-7313	imaging	_
44-27	7314-7321	weights	_
44-28	7322-7323	(	_
44-29	7324-7327	one	_
44-30	7328-7331	per	_
44-31	7332-7340	modality	_
44-32	7341-7342	)	_
44-33	7343-7350	related	_
44-34	7351-7353	to	_
44-35	7354-7358	each	_
44-36	7359-7361	IC	_
44-37	7362-7363	.	_

45-1	7364-7375	Significant	_
45-2	7376-7382	MANOVA	_
45-3	7383-7390	omnibus	_
45-4	7391-7396	tests	_
45-5	7397-7401	were	_
45-6	7402-7410	followed	_
45-7	7411-7413	up	_
45-8	7414-7418	with	_
45-9	7419-7426	planned	_
45-10	7427-7436	contrasts	_
45-11	7437-7438	.	_

